Item 7.01. Regulation FD Disclosure.

On October 12, 2021, Protara Therapeutics, Inc. (the "Company") issued a press release entitled "Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer," a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall the information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.




Item 8.01. Other Events.



On October 12, 2021, the Company made available a Corporate Presentation on the Investor Relations page of the Company's website, which will be used at investor and other meetings. A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company does not undertake to update this presentation.





                                       1

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated October 12, 2021, issued by the Registrant.
99.2            Protara Therapeutics, Inc. Corporate Presentation, October 2021.
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       2

© Edgar Online, source Glimpses